|
|
|
|
||
PANEL: TARGETED IMMUNOTHERAPIES FOR ONCOLOGYGood discussion of TCR's vs. CAR-T. At the 28 minute mark discussion of new technologies. Novartis' Usman Azam specifically mentions ZFN's as well as CRISPR and TALEN. Pfizer already backing TALEN through Cellectis, CRISPR too young and IP too murky with little clarity on who has the preeminent IP. Good chance of a Novartis-Sangamo hookup, imho. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
69322 | Re: PANEL: TARGETED IMMUNOTHERAPIES FOR ONCOLOGY | Aguacero | 15 | 11/25/2014 6:55:48 PM |
69335 | Re: PANEL: TARGETED IMMUNOTHERAPIES FOR ONCOLOGY | andybaron | 30 | 11/26/2014 7:15:13 PM |